PEMIGATINIB for Cholangiocarcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 431 adverse event reports in the FDA FAERS database where PEMIGATINIB was used for Cholangiocarcinoma.

Most Reported Side Effects for PEMIGATINIB

Side Effect	Reports	%	Deaths	Hosp.
Off label use	114	16.1%	28	19
Disease progression	103	14.5%	38	13
Death	76	10.7%	76	6
Fatigue	72	10.2%	5	7
Alopecia	53	7.5%	2	5
Hyperphosphataemia	46	6.5%	10	11
Cholangiocarcinoma	44	6.2%	19	4
Diarrhoea	42	5.9%	0	10
Constipation	37	5.2%	2	4
Drug ineffective	37	5.2%	13	3
Hospitalisation	35	4.9%	0	34
Nausea	35	4.9%	5	5
Decreased appetite	34	4.8%	3	5
Stomatitis	31	4.4%	2	6
Dry mouth	30	4.2%	1	2